Benitec Biopharma
Biotechnology, 3940 Trust Way, Hayward, California, 94545, United States, 11-50 Employees
Phone Number: +61**********
Who is BENITEC BIOPHARMA
Benitec is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference (RNAi) with gene therapy with a goal of providing sustained, lon...
Read More
-
Headquarters: 3940 Trust Way, Hayward, California, 94545, United States
-
Date Founded: 2001
-
Employees: 11-50
-
Revenue: $10 Million to $25 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 8731
|
NAICS Code: 541714 |
Show More
Does something look wrong? Fix it. | View contact records from BENITEC BIOPHARMA
Benitec Biopharma Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Benitec Biopharma
Answer: Benitec Biopharma's headquarters are located at 3940 Trust Way, Hayward, California, 94545, United States
Answer: Benitec Biopharma's phone number is +61**********
Answer: Benitec Biopharma's official website is https://benitec.com
Answer: Benitec Biopharma's revenue is $10 Million to $25 Million
Answer: Benitec Biopharma's SIC: 8731
Answer: Benitec Biopharma's NAICS: 541714
Answer: Benitec Biopharma has 11-50 employees
Answer: Benitec Biopharma is in Biotechnology
Answer: Benitec Biopharma contact info: Phone number: +61********** Website: https://benitec.com
Answer: Benitec is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference (RNAi) with gene therapy with a goal of providing sustained, long-lasting silencing of disease-causing genes from a single administration. Benitec is using its technology, called DNA-directed RNA interference (ddRNAi) to develop a pipeline of product candidates for the treatment of several chronic and life-threatening human diseases , including oculopharyngeal muscular dystrophy (OPMD) and hepatitis B. By combining the specificity and gene silencing effect of RNAi with gene therapy, ddRNAi has the potential to produce long-lasting silencing of disease-causing genes from a single administration, which could minimize the requirement for patients to take regular doses of medicine. Benitecs objective is to become the leader in discovering, developing, clinically validating and commercializing ddRNAi-based therapeutics for a range of human diseases with high unmet clinical need or large patient populations and, as a result, provide a better life for patients with these diseases.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Powered by
Sign in to CIENCE GO Data to uncover contact details
Free credits every month